ON THE RESULTS OF THE DETECTION OF VARIANT VARIANTS AND THE ASSOCIATION OF POLYMORPHISM IIE 105VAL OF THE GSTP1 GENE IN THE MECHANISM OF THE DEVELOPMENT OF ASHIRMAN'S SYNDROME IN THE UZBEK POPULATION

Asherman's syndrome or intrauterine synechia is one of the urgent problems of obstetric practice, characterized by the formation of adhesions and outgrowths of the endometrium with its sclerosis and fibrosis. The search for pathogenetic aspects of morbidity is a priority area of medical science. The aim of the study was to study allelic variants and the association of polymorphism IIe 105Val of the GSTP1 gene of the xenobiotic biotransformation enzyme in the mechanism of the development of Ashirman's syndrome. Material and research methods. We examined 26 patients with Ashirman's syndrome aged 19 to 42 years, who were observed at the clinic of RSSPMC A&G of the Ministry of Health of the Republic of Uzbekistan. All patients underwent clinical, functional, molecular genetic and statistical studies. The control group consisted of 22 women of healthy reproductive age of the corresponding age. Research results. Molecular genetic studies of the association of IIe 105 Val genotype polymorphism of the GSTP1 gene revealed the presence of favorable A/A genotypes - 7.7% (2/26), which was 11.8 times lower than in the control group. (χ2=33.5 p<0.0008; OR=0.01; 95%CI 0.0-0.06). Whereas the heterozygous genotype A/G of the GSTP1 gene in the main group of patients was 65.4% (17/26), which was 7.2 times higher than in the control healthy individuals. (χ2=33.5 p<0.0008; OR=18.9; 95%CI 3.58-99.64). And the unfavorable homozygous genotype G/G of the GSTP1 gene was not determined in the control group, while in the main group it was 26.9% (7/26). (χ2=33.47 p<0.0008; OR=17.31; 95% CI 0.93-322.9). Conclusion: The analysis of molecular genetic studies showed that the carriage of the heterozygous genotype of the GSTP1 gene polymorphism can be a predisposition factor to the development of Ashirman's syndrome in women of the Uzbek population, increasing its risk by 18.9 times (OR = 19.9). (χ2=33.5 p<0.0008; OR=18.9; 95%CI 3.58-99.64)